NCT01313962View on ClinicalTrials.gov

Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Influenza
Interventions
DRUG

Flufirvitide-3 0.05 mg single dose

Nasal Spray

DRUG

Flufirvitide-3, 0.1 mg single dose

Nasal spray

DRUG

Flufirvitide-3, 0.2 mg single dose

nasal spray

DRUG

Flufirvitide-3, 0.4 mg single dose

Nasal spray

OTHER

Placebo

Nasal spray

Trial Locations (1)

66211

Quintiles Phase One Services, Overland Park

Sponsors
All Listed Sponsors
lead

Autoimmune Technologies, LLC

INDUSTRY

NCT01313962 - Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects | Biotech Hunter | Biotech Hunter